Home › Stocks › Pharma & healthcare stocks › Ipca Labs
Pharma & healthcare stocks Valuation research

Ipca Labs fair value — pain, malaria and Unichem

Ipca is known for pain and anti-malarial medicines and their ingredients. Buying Unichem Laboratories in 2023 added a US and European generics business.

FairStocks Research
Updated 16 Nov 2026 · 4 min read
| NSE: IPCALAB ₹1,884
On this page ▾
  1. The business
  2. What the market assumes
  3. The ten-year record
  4. How it is valued
  5. What decides the value
  6. What could go wrong
  7. The full valuation
  8. Questions
Ipca Labs (IPCALAB) fair value — is it overvalued? Price ₹1,884, P/E 34.1, P/B 5.93, ROE —. Based on 10 years of reported financials. FairStocks.
Ipca Labs at a glance. Share price, P/E, P/B and the ten-year revenue trend, from filed accounts. Updated 16 Nov 2026.
In 30 seconds

The market expects Ipca Labs to carry on much as it has.

At today’s share price, buyers are assuming Ipca Labs grows about 13% a year, forever. Over the last ten years it actually grew about 13% a year. The two are close, so the share price does not need the business to improve or to stumble. It needs it to keep doing roughly what it already does.

  • How it is valued: Discounted cash flow.
  • What the price assumes: 13% growth, against 13% the model takes from its own record.
  • Ten-year record: Between FY2018 and FY2026, Ipca Labs' revenue went from ₹3,284 crore to ₹9,646 crore — it compounded at about 14% a year over 8 years.
  • Biggest swing factor: India brands. Main risk: FDA issues.
Price
₹1,884
Market cap
₹0.48L Cr
P/E
34.1
P/B
5.93
See Ipca's fair value and the full DCFEvery step of the Ipca Labs working, the scenarios and the report Free during launch →

01A Mumbai drugmaker with integrated APIs

Ipca Laboratories, run by the Godha family, sells branded medicines in India — pain relief brands such as Zerodol, anti-malarials and cardiovascular drugs — and makes many of its own active ingredients.

In 2023 it bought a majority stake in Unichem Laboratories, adding generics businesses in the US and Europe.

02What the market is assuming

Work backwards from today's share price and you can see what buyers are quietly taking for granted. Here is the growth that price implies for Ipca Labs, next to what the model assumes from the company's own record.

Market expects
13%
growth priced into today's price
Model assumes
13%
growth the model assumes

The further apart these two numbers are, the bigger the bet a buyer at today's price is making.

03Ipca Labs' record, in plain numbers

Between FY2018 and FY2026, Ipca Labs' revenue went from ₹3,284 crore to ₹9,646 crore — it compounded at about 14% a year over 8 years. Net profit grew from ₹239 crore to ₹1,184 crore, about 22% a year — faster than revenue, so margins widened. In FY2026 it kept 12.3% of revenue as net profit — against a low of 6.8% in FY2024 and a high of 21.1% in FY2021. The latest year added 7.9% to revenue, well behind its own long-run pace.

Reading the record. The FY2024 revenue jump reflects consolidating Unichem; FY2021's peak profit came from pandemic-era demand.
Revenue₹0.03L → ₹0.10L Cr
181920212223242526
Earnings per share₹19.0 → ₹45.0
181920212223242526
Return on equity15.4% → 29.5%
1920212223242526

Revenue and earnings per share in ₹, return on equity and leverage as ratios — all from the filed statements.

Revenue and net profit by year (₹ crore)
YearRevenueNet profitMargin
FY20183,2842397.3%
FY20193,77344211.7%
FY20204,64960413.0%
FY20215,4201,14121.1%
FY20225,83089015.3%
FY20236,2444797.7%
FY20247,7055236.8%
FY20258,9407858.8%
FY20269,6461,18412.3%

04How Ipca Labs gets valued — and why

Discounted cash flow

This business is valued on the cash it is expected to generate, discounted back at its cost of capital — with growth taken from its own ten-year record rather than from guidance.

05What decides Ipca Labs' value

India brands

Pain and chronic therapies drive profit.

Unichem integration

Improving Unichem's margins adds value.

APIs

Ingredient sales follow global demand.

Exports

Branded and generic exports add growth.

06What could go wrong

  • FDA issues. Plant inspections have affected US sales before.
  • Price controls. Indian price caps limit some products.
  • Integration. Unichem's turnaround may take time.

07What the full Ipca valuation shows

Model value per share
₹0,000
Upside
+00%
Call
XXXX

Sign in free to see the complete Ipca Labs valuation

  • ✓Fair value per share — from a ten-year discounted cash flow, every step shown
  • ✓The Workbench — change revenue growth, the discount rate or terminal growth and watch Ipca's value move
  • ✓Bull, base and bear cases — and exactly which assumptions move between them
  • ✓Peer comparison — against Alkem, Torrent Pharma and other drugmakers
  • ✓Downloadable report — the full write-up, yours to keep
See Ipca's fair value and the full DCF — free
Free during launch · unlimited valuations · no card required

08Questions people ask about Ipca Labs

What is Ipca known for?

Pain-relief and anti-malarial medicines and their ingredients.

What is Unichem Laboratories?

A drugmaker Ipca bought a majority of in 2023, with US and European generics.

Who runs Ipca?

The Godha family.

Is Ipca Labs overvalued?

At ₹1,884 the market is pricing in roughly 13% sustained growth, against the ~13% its own record supports. That is close to what it has delivered, so the price is broadly consistent with the company simply continuing as it has.

What is the intrinsic value of Ipca Labs?

It is computed from the filed financial statements using the method that fits this business (discounted cash flow), with every assumption shown alongside the result. The per-share figure and the full working are in the report.

How much debt does Ipca Labs carry?

Debt to equity stands at 0.01, down from 0.09 at the start of the period — the balance sheet is a core input to the cost of capital used here.

About this research

Written by the FairStocks research team from Ipca Labs' filed accounts and last reviewed 5 Oct 2026; the figures refresh as new results are filed. Every valuation uses the method that fits the business and shows its assumptions — see a fully worked example or the valuation guides. Educational research, not investment advice.

See Ipca's fair value and the full DCFUnlock free